Provided by Tiger Trade Technology Pte. Ltd.

CG Oncology Inc.

54.73
+1.663.13%
Post-market: 54.60-0.1300-0.24%17:22 EST
Volume:1.05M
Turnover:57.29M
Market Cap:4.41B
PE:-28.28
High:55.17
Open:53.20
Low:52.17
Close:53.07
52wk High:57.40
52wk Low:14.80
Shares:80.67M
Float Shares:65.44M
Volume Ratio:0.45
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9350
EPS(LYR):-1.4087
ROE:-24.74%
ROA:-17.56%
PB:6.42
PE(LYR):-38.85

Loading ...

CG Oncology Is Maintained at Overweight by Piper Sandler

Dow Jones
·
17 hours ago

CG Oncology price target raised to $70 from $55 at Piper Sandler

TIPRANKS
·
Yesterday

CG Oncology Expands At-The-Market Equity Offering Capacity

TIPRANKS
·
Jan 14

CG Oncology Inc Files for Offering of up to $550 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
Jan 14

CG Oncology Director James Mulay Reports Disposal of Common Shares

Reuters
·
Jan 14

CG Oncology Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 13

Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating

MT Newswires Live
·
Jan 12

Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
Jan 11

Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology

TIPRANKS
·
Jan 10

CG Oncology price target raised to $66 from $62 at Truist

TIPRANKS
·
Jan 10

CG Oncology price target raised to $93 from $89 at Morgan Stanley

TIPRANKS
·
Jan 10

CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk

Dow Jones
·
Jan 10

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

Benzinga
·
Jan 10

CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday

Benzinga_recent_news
·
Jan 10

CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target

TIPRANKS
·
Jan 10

CG Oncology rises 16.0%

TIPRANKS
·
Jan 09

CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline

TIPRANKS
·
Jan 09

BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc

Reuters
·
Jan 09

CG Oncology to Share Data for Investigational Bladder Cancer Therapy Nearly a Year Early

MT Newswires Live
·
Jan 09

CG Oncology to Report PIVOT-006 Phase 3 Topline Data for Intermediate-Risk NMIBC in First Half of 2026

Reuters
·
Jan 09